0001839882-22-022703.txt : 20221003 0001839882-22-022703.hdr.sgml : 20221003 20221003165056 ACCESSION NUMBER: 0001839882-22-022703 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220928 FILED AS OF DATE: 20221003 DATE AS OF CHANGE: 20221003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Booth Robert F. CENTRAL INDEX KEY: 0001507567 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36866 FILM NUMBER: 221288132 MAIL ADDRESS: STREET 1: C/O PHARMACYCLICS, INC. STREET 2: 995 EAST ARQUES AVENUE CITY: SUNNYVALE STATE: CA ZIP: 94085 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Summit Therapeutics Inc. CENTRAL INDEX KEY: 0001599298 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 617-514-7149 MAIL ADDRESS: STREET 1: 2882 SAND HILL ROAD STREET 2: SUITE 106 CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: Summit Therapeutics plc DATE OF NAME CHANGE: 20150219 FORMER COMPANY: FORMER CONFORMED NAME: Summit Corp plc DATE OF NAME CHANGE: 20140205 4 1 booth-form4_093022.xml FORM 4 X0306 4 2022-09-28 0 0001599298 Summit Therapeutics Inc. SMMT 0001507567 Booth Robert F. C/O SUMMIT THERAPEUTICS INC. 2882 SAND HILL ROAD, SUITE 106 MENLO PARK CA 94025 1 0 0 0 Stock Option (right to buy) 1.21 2022-09-28 4 A 0 200000 A 2032-09-28 Common Stock 200000 200000 D Stock Option (right to buy) 1.21 2022-09-28 4 A 0 6250 A 2032-09-28 Common Stock 6250 206250 D The option was granted on September 28, 2022. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on September 28, 2023. The option was granted on September 28, 2022 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days the Reporting Person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2022. Not applicable. /s/ Ankur Dhingra, as Attorney-in-Fact for Robert F. Booth 2022-10-03